Human Herpesvirus 8 (HHV-8) Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Human Herpesvirus 8 (HHV-8) Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is a gamma herpesvirus that infects various cell types, including endothelial cells, lymphocytes, and dendritic cells. HHV-8 is the etiological agent of Kaposi’s sarcoma (KS), a vascular tumor that often affects immunocompromised individuals, such as those with AIDS or organ transplant recipients. HHV-8 is also associated with rare lymphoproliferative disorders such as primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). The transmission of HHV-8 is not fully understood, but sexual contact, blood transfusion, and saliva exchange are possible routes. The prevalence of HHV-8 infection varies widely across different geographic regions and populations, ranging from 1% to 80%. Most HHV-8 infections are asymptomatic and latent, but reactivation can occur under conditions of immune suppression or inflammation. There is currently no vaccine or specific treatment for HHV-8 infection or its related diseases.
The Human Herpesvirus 8 (HHV-8) Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Human Herpesvirus 8 (HHV-8) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Herpesvirus 8 (HHV-8) Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Human Herpesvirus 8 (HHV-8) Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 2 molecules, with 2 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Human Herpesvirus 8 (HHV-8) Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Human Herpesvirus 8 (HHV-8) Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Human Herpesvirus 8 (HHV-8) Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AlloVir IncMicrobiotix Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Human Herpesvirus 8 (HHV-8) Infections reports